The ISAR-TRIPLE trial is the first trial evaluating the optimal duration of clopidogrel therapy in patients treated with DES who have an indication for OAC. The principal finding was that the primary endpoint—a composite of death, MI, ST, stroke, or TIMI major bleeding, also referred to as net clinical outcome—was not superior after a 6 ...

2015年4月29日 · The need for triple therapy with aspirin, clopidogrel, and a vitamin K antagonist is a commonly encountered clinical scenario in patients undergoing percutaneous coronary intervention (PCI), with concomitant conditions such as atrial fibrillation (AF) or venous thromboembolism (VTE).

2015年4月28日 · Background: Patients receiving oral anticoagulation (OAC) who undergo drug-eluting stent (DES) implantation require additional dual antiplatelet therapy with aspirin and clopidogrel. Such triple therapy confers an elevated bleeding risk, and its …

2015年4月29日 · 日发表于《美国心脏病学会杂志》的 isar-triple 试验称，口服抗凝血剂和阿司匹林的患者在支架置入后加用 6 周氯吡格雷治疗与 6 个月三联疗法相比并无净临床益处。

The 2015 Intracoronary Stenting and Antithrombotic Regimen-Testing of a 6-Week Versus a 6-Month Clopidogrel Treatment Regimen in Patients with Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-Eluting Stenting (ISAR-TRIPLE) trial randomized 614 patients to 6 weeks of clopidogrel therapy (in addition to OAC and aspirin) or 6 ...

2014年9月11日 · ISAR TRIPLE is the largest randomized trial to date investigating triple therapy after stenting and the first trial evaluating duration of triple therapy. Study investigators randomized 614 patients with DES implantation to either six …

In summary, ≥44% of the stents implanted in the study included newer-generation DES (bioabsorbable/biodegradable stents). These could potentially affect the efficacy and safety of this strategy when applied to a larger unrestricted population. Table 1. Stent Types Used in the ISAR-TRIPLE Trial. Values are n (%).

The optimal duration of triple therapy after PCI remains to be defined, and 2 factors need consider-ation. First, the risk of stent thrombosis (ST) is high-est in the early phase after PCI and declines over time (7). Secondly, the risk of bleeding with triple therapy increases with duration of therapy(8,9) and intensity of OAC (10).

Study design: The ISAR-TRIPLE is a randomized, open-label trial that examines the restriction of clopidogrel therapy from 6 months to 6 weeks after DES implantation in the setting of concomitant aspirin and oral anticoagulant. Patients are randomized in a 1:1 fashion to either 6-week or 6-month clopidogrel therapy.

2014年9月25日 · WOEST 研究主要比较三联治疗（阿司匹林 + 氯吡格雷 + 抗凝药）与双联治疗（氯吡格雷 + 抗凝药），研究表明双联治疗较三联治疗显著减少任意出血和缺血并发症， Sarafoff 认为双联治疗更减少缺血并发症令人费解。 ISAR-TRIPLE 研究纳入 614 名植入药物洗脱支架的患者，并被随机分为氯吡格雷 6 周和 6 个月组（所有患者均服用阿司匹林和维生素 K 拮抗剂）。 研究表明两组 9 个月主要复合终点（死亡、心梗、支架内血栓形成、卒中或 TIMI 出血）无差异 …